- Home
- KROS vs OLP Comparison
KROS vs OLP Comparison
Compare KROS & OLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- OLP
- Stock Information
- Founded
- KROS 2015
- OLP 1982
- Country
- KROS United States
- OLP United States
- Employees
- KROS N/A
- OLP N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- OLP Real Estate Investment Trusts
- Sector
- KROS Health Care
- OLP Real Estate
- Exchange
- KROS Nasdaq
- OLP Nasdaq
- Market Cap
- KROS 460.6M
- OLP N/A
- IPO Year
- KROS 2020
- OLP N/A
- Fundamental
- Price
- KROS $11.00
- OLP $25.75
- Analyst Decision
- KROS Buy
- OLP Strong Buy
- Analyst Count
- KROS 11
- OLP 1
- Target Price
- KROS $45.33
- OLP $28.00
- AVG Volume (30 Days)
- KROS 2.1M
- OLP 46.6K
- Earning Date
- KROS 02-26-2025
- OLP 03-04-2025
- Dividend Yield
- KROS N/A
- OLP 7.06%
- EPS Growth
- KROS N/A
- OLP 51.11
- EPS
- KROS N/A
- OLP 1.63
- Revenue
- KROS $651,000.00
- OLP $89,142,000.00
- Revenue This Year
- KROS $303.27
- OLP N/A
- Revenue Next Year
- KROS N/A
- OLP $4.71
- P/E Ratio
- KROS N/A
- OLP $15.65
- Revenue Growth
- KROS 8037.50
- OLP N/A
- 52 Week Low
- KROS $9.78
- OLP $19.75
- 52 Week High
- KROS $73.00
- OLP $30.45
- Technical
- Relative Strength Index (RSI)
- KROS 24.79
- OLP 42.45
- Support Level
- KROS $11.04
- OLP $25.08
- Resistance Level
- KROS $11.99
- OLP $25.93
- Average True Range (ATR)
- KROS 0.60
- OLP 0.53
- MACD
- KROS 1.20
- OLP 0.09
- Stochastic Oscillator
- KROS 43.99
- OLP 52.99
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.